Abstract: The present disclosure relates to a composition for preventing or treating wound. The composition according to the present disclosure contains, as an active ingredient, an indirubin derivative alone or one or more selected from a group consisting of an indirubin derivative, an Euodia sutchuenensis Dode extract, methyl vanillate, hesperidin and quercitrin, and thus can be used as a pharmaceutical composition capable of promoting wound healing and reducing scarring not only in a normal state but also in a diabetic state. Furthermore, since the composition exhibits excellent effects in healing diabetic wound as well as general wound, it can be usefully used as a pharmaceutical composition, cosmetic composition or food composition for alleviating, preventing or treating general wound or diabetic wound, or as a veterinary composition for treating diabetic wound.

Abstract: Therapeutic compositions comprising one or more agents that inhibit CXXC5-DVL interface and/or that enhance the activity of GLP-1, and methods of administering those therapeutic compositions to model, treat, reduce resistance to treatment, prevent and diagnose a condition/disease associated with neurodegenerative diseases or a related clinical condition thereof, are disclosed.

Abstract: A composition for promoting longitudinal bone growth, according to the present invention, promotes the proliferation of the chondrocytes and the differentiation of the osteoblasts and has effects of simultaneously increasing longitudinal bone length and thickness (bone density), and thus has an advantage of being widely prescribable to various age groups, thereby being usable as a pharmaceutical composition for promoting the growth of longitudinal bone length and thickness. An indirubin derivative according to the present invention has prevention or treatment effects through oral administration. In addition, unlike conventional therapeutic agents, the pharmaceutical composition for preventing or treating bone diseases of the present invention is a stable compound, which is known to be substantially noncytotoxic to the human body, and is a material of which adverse effects have not been identified and has excellent treatment effects for bone diseases and osteogenesis imperfecta.